The Alpha 1 Adrenergic Receptor pipeline drugs market research report outlays comprehensive information on the Alpha 1 Adrenergic Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Alpha 1 Adrenergic Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Genito Urinary System, Ophthalmology, and Immunology which include the indications Schizophrenia, Post-Traumatic Stress Disorder (PTSD), Benign Prostatic Hyperplasia, Acute Renal Failure (ARF) (Acute Kidney Injury), Presbyopia, Ptosis, and Anaphylaxis. It also reviews key players involved in Alpha 1 Adrenergic Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Alpha 1 Adrenergic Receptor pipeline targets constitutes close to 46 molecules. Out of which, approximately 46 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 4, 11, 10, 8, 3, and 8 respectively.
Alpha 1 Adrenergic Receptor overview
Alpha-1 adrenergic receptors (α1-ARs) are a family of G protein-coupled receptors (GPCRs) that are activated by the catecholamines norepinephrine and epinephrine. They are found in a variety of tissues throughout the body, including the cardiovascular system, smooth muscle, liver, and kidney. α1-ARs play a role in a number of physiological processes, including vasoconstriction, smooth muscle contraction, glycogenolysis, and lipolysis.
For a complete picture of Alpha 1 Adrenergic Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
